New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Precision medicine is one of the most talked about trends in healthcare. The promise is improved health outcomes and patient satisfaction, gained through an understanding of individual variability in genes, environment, and lifestyle. Recent commentators suggest that many of the technologies required to realize this goal already exist—and predict much
Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk